Biocon Launches Denosumab Biosimilars in U.S.
BENGALURU, India & BRIDGEWATER, New Jersey, United States, April 7, 2026 Biocon Limited announced the U.S. commercial launch of...
biosimilars
Advertisement
CuraTeQ Reports Positive Phase 3 Results for BP11 Biosimilar
Hyderabad, India, April 7, 2026 Phase 3 Trial Confirms Biosimilar Equivalence In a significant milestone for biosimilar drug development,...
Alvotech Reports Positive PK Data for Entyvio Biosimilar
REYKJAVIK, Iceland, Feb. 5, 2026 —Alvotech announced positive top-line results from a pivotal pharmacokinetic (PK) study evaluating AVT80, its...
Alvotech Strengthens Biosimilar Growth With $100M Financing
REYKJAVÍK, ICELAND | December 31, 2025 — Alvotech announced it has secured a USD 100 million senior term loan...
Alvotech Launches Europe’s First Golimumab Biosimilar
REYKJAVÍK, Iceland; LONDON, United Kingdom — December 22, 2025 — Alvotech has announced the European launch of the world’s...
Advertisements
FDA Grants Interchangeability for Celltrion’s Denosumab Biosimilars
Incheon, South Korea, October 30, 2025 — Celltrion, Inc., a global biopharmaceutical company specializing in biosimilars and innovative biologics,...
Celltrion Gains FDA Nod for YUFLYMA Pediatric Use Expansion
Incheon, South Korea – October 16, 2025 – CelltrionUSA, a subsidiary of Celltrion Inc., announced that the U.S. Food...
Celltrion Secures FDA Approval for EYDENZELT® in Multiple Retinal Diseases
INCHEON, South Korea, Oct. 9, 2025 — Celltrion, Inc., a global biopharmaceutical innovator, announced that the U.S. Food and...
European Commission Approves Henlius and Organon’s Biosimilars for Bone Disorders
SHANGHAI, China & JERSEY CITY, NJ – September 19, 2025, Shanghai Henlius Biotech, Inc. (2696.HK) and Organon (NYSE: OGN)...
Biocon Biologics Wins FDA Nod for Denosumab Biosimilars
BENGALURU, India & BRIDGEWATER, N.J. – September 17, 2025 –Biocon Biologics Ltd. (BBL), a global leader in biosimilars and...
Advertisement
